- 5 Principles to Build Positive Patient-Provider Relationships
And those affects are not always good. Studies have shown that direct-to-consumer drug advertising has led to increasing in prescriptions for several types of drugs, including antidepressants, cholesterol drugs or statins in low-risk patients, or prescriptions to smoking cessation drugs before potential safety issues had been identified.
But although those potential negative affects are well-documented, less is known about how direct-to-consumer drug advertising can impact the patient-provider relationship. After all, providers want to do right by their patients, and that includes connecting patients with a medication that will make patients feel better and be healthier.
What happens when a patient brings a drug they have discovered through an advertisement into the clinic encounter, especially when that provider doesn’t believe the drug useful for the patient case?
Nothing particularly damaging, this latest study found, although there may still be room for healthcare to reconsider direct-to-consumer drug advertisements.
In a qualitative survey of 1,744 patients, about three-quarters said they were likely to ask their clinicians about a drug they saw in a direct-to-consumer advertisement; 26 percent reported that they already had.
Of those 26 percent, only 16 percent said they actually received a prescription to the drug they were asking for, opening up a new line of questioning about patient-provider relationships. Did the denial for the prescription affect how the patient and provider interacted or the quality of their rapport?
Not quite, the survey revealed. Only 5 percent of respondents said a provider’s denial of a requested prescription drug had caused an actual conflict between the two, and fewer than half of patients said they doubted their providers’ decisions. Sixteen percent said the denial of a requested prescription caused them to question their provider’s expertise. Another 23 percent of respondents said they may look for another clinician if their current clinician denied them a prescription to a brand name medication.
This could be the credit of an evolving healthcare industry, in which value-based care may help patients and providers understand the need for high-value but low-cost drugs.
“A refusal to prescribe an advertised prescription drug did not seem to have overtly adverse effects on the patient-provider relationship, such as motivating respondents to look for a different health care provider,” the researchers said. “These findings may reflect a shift in the larger health care paradigm toward formularies and value-based medicine, in which HCPs are focused on improving patients’ health by providing cost-effective, quality care, while balancing patient satisfaction.”
Although most patients may not know about value-based care, the culture of the healthcare landscape is trending toward high-value- low-cost care and patients may be cognizant of that.
There were other positive outcomes of patients discussing the medications they see in direct-to-consumer advertisements. In some cases, patients and providers were able to have a larger conversation about symptoms and drug side effects, deepening a patient’s understanding of her own health.
Knowing more about how patients — who are increasingly being viewed as healthcare consumers — engaged with direct-to-consumer drug advertisements will be important for providers, who serve as key intermediaries between patients and medications.
“This unique circumstance provides opportunities and challenges for HCPs seeking to provide optimal care to their patients,” the researchers concluded. “Consideration of patient attitudes toward DTCA and its potential impact on the patient-provider relationship could help HCPs, pharmaceutical companies, patients, and other stakeholders to foster good health outcomes.”
By Sara Heath